Similarly, in our breast cancer patients, genes that are often only targeted in the presence of additional personal and/or family history, such as NF1, TP53, and CDH1, added a minor increase in the diagnostic yield, but they established a molecular diagnosis for the underlying condition for these patients, providing clinical benefit. This evidence concerns the gene CDH1 and breast carcinoma.